ASND Share Price Performance
US$247.05
1.67 (0.68%)
27.8% undervalued intrinsic discount
US$342.08
Fair Value
Price US$247.05
AnalystConsensusTarget US$342.08
AnalystLowTarget US$254.97
Fair ValueUS$342.08
Share Pricen/a
Analysis Article • May 15
Ascendis Pharma A/S Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
ASND Community Narratives
AN
Fair Value
·Fair Value US$342.08 27.8% undervalued intrinsic discount
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$254.97 3.1% undervalued intrinsic discount
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long-acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Read more
AN
US$254.97
3.1% undervalued intrinsic discount
Fair Value
Profit Margin
32.17%
Future PE
23.78x
Price in 2029
US$312.01
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Catalysts About Ascendis Pharma Ascendis Pharma focuses on developing and commercializing long acting therapies for rare endocrine and growth disorders using its TransCon technology platform. What are the underlying business or industry changes driving this perspective?Read more
AN
US$342.08
27.8% undervalued intrinsic discount
Fair Value
Profit Margin
39.33%
Future PE
22.63x
Price in 2029
US$419.87
Trending Discussion
Recently Updated Narratives
AN
Long Term TransCon Pipeline Execution Will Shape Future Cash Flows And Business Durability
Fair Value: US$254.97 3.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Long Acting TransCon Therapies Will Reshape Rare Endocrine Treatment Over The Coming Years
Fair Value: US$342.08 27.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Ascendis Pharma A/S Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- 7.98
- 89.04%
- 57.28%
- 152.9%
About ASND
- Founded
- 2006
- Employees
- 1189
- CEO
- WebsiteView website
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
